Dyadic International Inc (NASDAQ:DYAI) announced Friday that it extended its R&D pact through June 2022 with VTT Technical Research Centre of Finland Ltd, a leading synthetic biology technology and research company.
Under the terms of the extended agreement, Dyadic will fund VTT to continue to apply its advanced synthetic biology methods, including its patented synthetic promoters to further engineer the company's C1 cell line.
Jupiter, Florida-based Dyadic leverages its proprietary C1 technology — an industrially proven fungal gene expression technology — to help bring biologic vaccines, enzymes, proteins, biosimilars, and drugs to market faster and at a lower cost.
READ: Dyadic's red-hot C1 gene expression technology gets biologic vaccines, drugs to market swiftly at lower cost
The agreement also provides for potential milestone payments to VTT for achieving specified productivity levels and glycosylation properties within specified timelines.
Dyadic will provide additional funding to VTT for certain Dyadic internal research projects and other third-party collaborations, including Sanofi and the Serum Institute of India. In addition, Dyadic and its C1 sublicensees will have the right to use for an access fee the synthetic tools developed by VTT to further increase the productivity and yield of C1, said the company in a statement.
"We are very pleased to continue our relationship with VTT which began in 2016 and have access to its patented genetic tools and their substantial cell engineering expertise," said Dyadic International CEO Mark Emalfarb. "Our goal is to further develop our C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products at flexible commercial scales."
Dyadic has patented its proprietary filamentous fungus, Myceliophthora thermophila, nicknamed C1 and the associated molecular tools used to engineer the C1 cells to express and manufacture large volumes of low-cost biologic products such as enzymes and proteins. The C1 fungus, is a living cell that has been bioengineered by Dyadic scientists for more than two decades.
Amping up protein production
"Through our collaborative scientific efforts with VTT, the data generated has exceeded our expectations on several fronts including the pace of development and level of protein productivity and stability,” said Dr Ronen Tchelet, vice presidnet of R&D at Dyadic International. “A recent example is the very high expression level reached of a full-length monoclonal antibody (mAb) of 22 grams per liter in seven days."
Meanwhile, VTT which has been doing advanced research for clients for nearly 75 years, said it was “very excited” to continue its collaboration with Dyadic.
“VTT's goal is to solve global challenges and by doing that accelerate growth and wellbeing in society and for our customers,” said Jussi Manninen, executive vice president at VTT. “Working together with Dyadic has already resulted in record levels of productivity of several different types of proteins using very low cost defined synthetic media. Given our strong background in fungal molecular biology and bioprocessing, we look forward to further enhancing C1's capabilities to further expand the range of growth opportunities for Dyadic."
—(Updates with fresh quotes from company officials)—
Contact Uttara Choudhury at [email protected]